Iovance Biotherapeutics Inc (NAS:IOVA)
$ 8.88 -0.115 (-1.28%) Market Cap: 2.48 Bil Enterprise Value: 2.21 Bil PE Ratio: 0 PB Ratio: 3.65 GF Score: 39/100

Q2 2022 Iovance Biotherapeutics Inc Earnings Call Transcript

Aug 04, 2022 / 08:30PM GMT
Release Date Price: $12.54 (+4.15%)
Operator

Welcome to the Iovance Biotherapeutics Second Quarter and First Half 2022 Financial Results and Corporate Update Conference Call. My name is Andrew, and I will be your operator for today's call. (Operator Instructions) Please note that this call is being recorded. I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sara, you may begin.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good afternoon, and thank you for joining us. Speaking on today's call, we have Dr. Fred Vogt, our Interim President and Chief Executive Officer; Dr. Igor Bilinsky, our Chief Operating Officer; James Ziegler, our Executive Vice President, Commercial; Dr. Friedrich Finckenstein, our Chief Medical Officer; and Jean-Marc Bellemin, our Chief Financial Officer; Dr. Madan Jagasia our Executive Vice President, Medical Affairs; and Dr. Raj Puri, our Executive Vice President. Regulatory Strategy and Translational Medicine are also available for the Q&A

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot